Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Cerevel Therapeutics Hldg Inc (CERE)

Cerevel Therapeutics Hldg Inc (CERE)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
44.96 +0.33 (+0.74%) 07/31/24 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 44.96 unch (unch) -
News & Headlines for Wed, Jul 31st, 2024
Is AbbVie Stock Outperforming the Nasdaq?

AbbVie has recently outperformed the Nasdaq, and Wall Street analysts are moderately optimistic about the stock’s prospects.

$NASX : 16,831.48 (+0.64%)
CERE : 44.96 (+0.74%)
ABBV : 179.10 (+2.31%)
BMY : 51.34 (+1.24%)
As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032

EQNX::TICKER_START (NYSE:OGEN),(NYSE:ABT),(NASDAQ:BIIB),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END

ABT : 127.96 (+0.85%)
OGEN : 0.1894 (-0.84%)
CERE : 44.96 (+0.74%)
ABBV : 179.10 (+2.31%)
PFE : 22.12 (+0.96%)
BIIB : 119.26 (+3.55%)
What Are Wall Street Analysts' Target Price for Abbvie Stock?

Despite AbbVie stock’s robust price performance compared to the broader market over the past year, Wall Street analysts are moderately bullish about the stock’s prospects.

WFC : 63.10 (+0.94%)
$SPX : 5,405.97 (+0.79%)
PPH : 83.28 (+1.55%)
CERE : 44.96 (+0.74%)
ABBV : 179.10 (+2.31%)
1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165?

Revenue growth during what should be a disastrous patent cliff is encouraging.

CERE : 44.96 (+0.74%)
ABBV : 179.10 (+2.31%)
Is AbbVie Stock a Buy Now?

Management pivoting a $300 billion company as quickly as it has is nothing short of remarkable.

CERE : 44.96 (+0.74%)
ABBV : 179.10 (+2.31%)
Is AbbVie Stock a Buy Now?

The company is grappling with losing Humira's patent protection in 2023.

IMGN : 31.23 (unch)
CERE : 44.96 (+0.74%)
ABBV : 179.10 (+2.31%)
4 Top Dividend Stocks Yielding More Than 4% to Buy Hand-Over-Fist This December

These companies offer above-average income streams that should continue rising.

VZ : 44.30 (+1.30%)
SRC : 42.31 (-1.56%)
BEPC : 26.91 (+2.01%)
CERE : 44.96 (+0.74%)
ABBV : 179.10 (+2.31%)
BEP : 21.58 (+1.08%)
O : 56.27 (+1.90%)
AbbVie Just Announced 2 Big Acquisitions: Is This Dividend King a No-Brainer Buy Right Now?

The big drugmaker went on a holiday shopping spree.

IMGN : 31.23 (unch)
AGN.AX : 0.695 (-4.14%)
CERE : 44.96 (+0.74%)
ABBV : 179.10 (+2.31%)
AbbVie's on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next?

Here's what's attracting lucrative buyout offers from big pharmaceutical companies these days.

IMGN : 31.23 (unch)
CERE : 44.96 (+0.74%)
ABBV : 179.10 (+2.31%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cerevel Therapeutics Holdings, Inc. - CERE

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cerevel Therapeutics Holdings, Inc. ("Cerevel" or the "Company") (NASDAQ: CERE)....

CERE : 44.96 (+0.74%)

Barchart Exclusives

These 2 Dividend Aristocrats Are Top Stocks to Buy in Times of Uncertainty
These companies offer consistent dividend growth and a strong industry presence. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar